Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

Jeffrey M. Hoeg, Martha B. Maher, Loren A. Zech, Kent R Bailey, Richard E. Gregg, Karl J. Lackner, Silvia S. Fojo, Michael A. Anchors, Marina Bojanovski, Dennis L. Sprecher, H. Bryan Brewer

Research output: Contribution to journalArticle

71 Scopus citations


Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction. Mevinolin, an inhibitor of endogenous cholesterol synthesis, has been shown to reduce LDL cholesterol concentrations in a subset of type II patients with heterozygous familial hypercholesterolemia (FH). Using a double-blind, randomized, crossover, placebo-controlled trial, the safety and efficacy of mevinolin were compared in 24 patients with type II HLP with heterozygous FH (n = 6) or without FH type II HLP (n = 18). Compared with placebo treatment, both apolipoprotein B and LDL cholesterol levels were reduced (p < 0.01) in both FH and non-FH patients by 28 to 34% with mevinolin treatment. In addition, high-density lipoprotein cholesterol levels were significantly increased (p < 0.001) in both patients with FH (16%) and those with non-FH type II HLP (14%). Patients had no serious or clinically significant adverse effects. Thus, mevinolin is a useful drug for treatment of most patients with elevated plasma LDL cholesterol concentrations.

Original languageEnglish (US)
Pages (from-to)933-939
Number of pages7
JournalThe American Journal of Cardiology
Issue number11
StatePublished - Apr 15 1986
Externally publishedYes


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hoeg, J. M., Maher, M. B., Zech, L. A., Bailey, K. R., Gregg, R. E., Lackner, K. J., Fojo, S. S., Anchors, M. A., Bojanovski, M., Sprecher, D. L., & Brewer, H. B. (1986). Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. The American Journal of Cardiology, 57(11), 933-939. https://doi.org/10.1016/0002-9149(86)90733-2